Human Leukocyte Antigen (HLA) and Killer-cell Immunoglobulin-like Receptor (KIR) Region Genomics in Immune-Mediated Diseases (U01 Clinical Trial Not Allowed)
This funding opportunity aims to support research on the connections between certain genetic regions (HLA and KIR) and diseases that are influenced by the immune system. The goals are to understand these connections better, explore the mechanisms behind them to find new treatments, and confirm these connections to enhance disease prediction in clinical settings.
Source
Award
Dates
Keywords
Supporting Links
Documents
Similar Opportunities
-
NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)
National Institutes of Health
-
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
National Institutes of Health ▸ National Cancer Institute
-
NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
National Institutes of Health
-
GREGoRi Innovation Projects (U01 Clinical Trial Optional)
National Institutes of Health
-
Multiple Sclerosis Fellowship (Minnesota)
Mayo Clinic
Find tens of thousands more opportunities — free
Scout accounts are free. Sign up to browse the full funding database, unlock the solicitation links and documents for this opportunity, and see how well each one fits your organization.
-
Tens of thousands of funding opportunities
Search and filter every grant and solicitation in Scout — all free, no credit card required.
-
Instant Fit Analysis
Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
-
Source links & full documents
Jump straight to the solicitation and download every attachment.
-
Save opportunities & track deadlines
Keep the opportunities that fit in one place and stay ahead of every due date.
Already have an account? Sign In
Trusted by 500+ Happy Customers